Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(3.34)
# 973
Out of 4,896 analysts
103
Total ratings
51.67%
Success rate
2.91%
Average return
Main Sectors:
Stocks Rated by Olivia Brayer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRNA Verona Pharma | Maintains: Overweight | $90 → $100 | $104.83 | -4.61% | 1 | Jun 11, 2025 | |
| UTHR United Therapeutics | Initiates: Overweight | $405 | $295.52 | +37.05% | 1 | Jun 2, 2025 | |
| VNDA Vanda Pharmaceuticals | Assumes: Overweight | $13 | $4.74 | +174.26% | 1 | May 14, 2025 | |
| BMRN BioMarin Pharmaceutical | Reiterates: Overweight | $90 | $58.10 | +54.91% | 15 | Feb 20, 2025 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Overweight | $480 | $468.85 | +2.38% | 22 | Feb 11, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $50 → $55 | $46.86 | +17.37% | 9 | Feb 4, 2025 | |
| GILD Gilead Sciences | Reiterates: Neutral | $80 | $109.64 | -27.03% | 10 | Dec 11, 2024 | |
| OMER Omeros | Reiterates: Neutral | n/a | $3.65 | - | 1 | Nov 14, 2024 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Neutral | $1,015 | $567.74 | +78.78% | 8 | Oct 23, 2024 | |
| AMGN Amgen | Reiterates: Overweight | $405 | $295.27 | +37.16% | 2 | Oct 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $220 | $314.94 | -30.15% | 23 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $10 | $8.80 | +13.64% | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6.5 | $3.77 | +72.41% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $56.80 | +26.76% | 1 | Apr 13, 2023 |
Verona Pharma
Jun 11, 2025
Maintains: Overweight
Price Target: $90 → $100
Current: $104.83
Upside: -4.61%
United Therapeutics
Jun 2, 2025
Initiates: Overweight
Price Target: $405
Current: $295.52
Upside: +37.05%
Vanda Pharmaceuticals
May 14, 2025
Assumes: Overweight
Price Target: $13
Current: $4.74
Upside: +174.26%
BioMarin Pharmaceutical
Feb 20, 2025
Reiterates: Overweight
Price Target: $90
Current: $58.10
Upside: +54.91%
Vertex Pharmaceuticals
Feb 11, 2025
Reiterates: Overweight
Price Target: $480
Current: $468.85
Upside: +2.38%
Bristol-Myers Squibb Company
Feb 4, 2025
Maintains: Neutral
Price Target: $50 → $55
Current: $46.86
Upside: +17.37%
Gilead Sciences
Dec 11, 2024
Reiterates: Neutral
Price Target: $80
Current: $109.64
Upside: -27.03%
Omeros
Nov 14, 2024
Reiterates: Neutral
Price Target: n/a
Current: $3.65
Upside: -
Regeneron Pharmaceuticals
Oct 23, 2024
Reiterates: Neutral
Price Target: $1,015
Current: $567.74
Upside: +78.78%
Amgen
Oct 22, 2024
Reiterates: Overweight
Price Target: $405
Current: $295.27
Upside: +37.16%
Oct 11, 2024
Reiterates: Neutral
Price Target: $220
Current: $314.94
Upside: -30.15%
Sep 16, 2024
Reiterates: Overweight
Price Target: $10
Current: $8.80
Upside: +13.64%
May 9, 2024
Reiterates: Overweight
Price Target: $6.5
Current: $3.77
Upside: +72.41%
Apr 13, 2023
Initiates: Overweight
Price Target: $72
Current: $56.80
Upside: +26.76%